# Camrelizumab Combined With SOX and/or Apatinib for Locally Advanced Gastric Cancer

> **NCT04792515** · PHASE2 · UNKNOWN · sponsor: **First Affiliated Hospital Xi'an Jiaotong University** · enrollment: 67 (estimated)

## Conditions studied

- Locally Advanced Gastric Cancer

## Interventions

- **DRUG:** Camrelizumab combined with SOX/ or apatinib

## Key facts

- **NCT ID:** NCT04792515
- **Lead sponsor:** First Affiliated Hospital Xi'an Jiaotong University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-01-01
- **Primary completion:** 2022-06-30
- **Final completion:** 2022-12-31
- **Target enrollment:** 67 (ESTIMATED)
- **Last updated:** 2021-03-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04792515

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04792515, "Camrelizumab Combined With SOX and/or Apatinib for Locally Advanced Gastric Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04792515. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*